the US is obsessed with disruption, they see disruption way too easily, and will back it in, for awhile at least, even if the threat is nebulous. thats why i was cautious on rmd in the mid $30's no risk built in. i raised it on seeking alpha a while ago and got howled down, not now.

there is now risk built into rmd in my view, the mid 20's i will have a real go at them. now hold a position

however i still stand by my view that if these pills are subsidied they will impact demand for rmd products to a meaningful degree. how much? even rmd may not know that.

thats my view at this point. just had shoulder surgery typing is difficult atm sorry.

With RMD down another 5% in the early going on the NYSE, it certainly looks like the knives have been sharpened, and the short attack is on.

It's interesting that everyone's talking about GLP-1 drugs and its impacts on the sleep apnea market.

A friend send me this FNArena article a week ago when we spoke about buying RMD: https://www.fnarena.com/index.php/2023/08/09/august-turns-resmed-into-nigel-nomates/

I couldn't find anything that happened "overnight" with the said clinical trial.

Perhaps the temptation to showcase one's understanding of GLP-1 is too intoxicating to suppress.

@Mujo interesting article and does help to explain some of the recent dramatic moves. The irony of the anti-obesity drugs could be that they reduce the mortality risk of these heavily overweight people and actually make them need CPAP machines for a longer total length of time.